Современные взгляды на диагностику нейролептической гиперпролактинемии
Рекомендуемое оформление библиографической ссылки:
Горобец Л.Н., Буланов В.С., Литвинов А.В., Мазо Г.Э. Современные взгляды на диагностику нейролептической гиперпролактинемии // Российский психиатрический журнал. 2018. №4. С. 56-63.
В научном обзоре с целью обоснования необходимости введения российских стандартов
диагностики и мониторинга синдрома нейролептической гиперпролактинемии у больных
с психическими расстройствами в процессе антипсихотической терапии приводятся
данные зарубежной и отечественной литературы по эпидемиологии, диагностическим
подходам, мониторингу и профилактике развития нейролептической гиперпролактинемии
у больных с расстройствами шизофренического спектра. Большинство исследователей
сходятся во мнении, что, несмотря на высокую частоту встречаемости нейролептической
гиперпролактинемии, до настоящего времени не разработаны алгоритмы диагностических
подходов для профилактики и минимизации указанного побочного эффекта при применении
антипсихотических препаратов.
Ключевые слова гиперпролактинемия, сексуальная дисфункция, галакторея, нарушения менструального цикла, антипсихотики
1. Gorobets LN, Mazo GE. Nejroehndokrinnye disfunkcii pri ispol'zovanii psihofarmakoterapii: klinika, diagnostika, faktory riska i korrekciya. Zh Nevrol Psikhiatr Im SS Korsakova. 2014;10:85–93. Russian. 2. Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics – a review. Hum Psychopharmacol. 2010 Jun-Jul;25(4):281-97. doi: 10.1002/hup.1116. 3. Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol. 2008 Mar;22(2 Suppl):90-7. doi:10.1177/0269881107087373. 4. Peveler RC, Branford D, Citrome L, et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol. 2008;22(2): 98–103. 5. McEvoy JP, Scheifler PL, Frances A (Eds). Expert consensus guideline series. Treatment of schizophrenia. Journal of Clinical Psychiatry. 1999;60(11):1–80. 6. Halbreich U, Kahn LS. Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology. 2003;28:16–28. 7. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry. 2002;159:133–5. 8. Brown WA, Laughren T. Low serum prolactin and early relapse following neuroleptic withdrawal. Am J Psychiatry. 1981;138:237–9. 9. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry. 2001;158:360–9. 10. Gorobec LN. [The problem of neuroendocrine dysfunctions in patients with schizophrenic spectrum disorders (analysis of results of psychiatrists interviews)]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2015;(5):79-84. Russian. 11. Lehman AF, Lieberman JA, Dixon LB, et al. American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition/ Am J Psychiatry. 2004;161(Suppl.):1–56. 12. Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry. 2005;50(1):7–57. 13. National Collaborating Centre for Mental Health Bipolar disorder quick reference guide. London (UK): National Institute for Health and Clinical Excellence. 2006. Available at http://www.nice.org.uk/page.aspx?o=CG038quickrefguide. 14. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders (2005) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry. 2005;39:1–30. 15. Moore TA, Buchanan RW, Buckley PF, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. Journal of Clinical Psychiatry. 2007;68:1751–62. 16. National Institute for Clinical Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance. No. 43. London: NICE. 2002. 17. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161:1334–49. 18. Janssen LP. Risperdal (risperidone) Tablets/Oral Solution, Risperdal M-Tab (risperidone) Orally Disintegrating Tablets. Available at: http://www.risperdal.com/active/janus/en_US/assets/comon/company/pi/risperdal.pdf. Accessed April 13, 2007. 19. Taylor D, Kerwin R, Paton C. The Maudsley 2005–2006. Prescribing Guidelines (8th Rev Ed editon). Taylor & Francis Ltd, 2005;30–3. 20. National Institute for Clinical Excellence. Schizophrenia, Full national clinical guideline on core interventions in primary and secondary care. 2008. http://www.nice.org.uk/page.aspx?o=42460. 21. Falkai P, Wobrock T, Lieberman J, et al. WFSBP Task Force on Treatment Guidelines for Schizophrenia (2006). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia. World J Biol Psychiatry. 2006;7:5–40. 22. International Psychopharmacology Algorithm Project. Antipsychoticinduced hyperprolactinemia. Available at: http://www.ipap.org/schiz/pdf/hyperprolactinaemia.pdf. Accessed April 16, 2007. 23. National Collaborating Centre for Mental Health (2006) Bipolar disorder quick reference guide. London (UK): National Institute for Health and Clinical Excellence. Available at http://www.nice.org.uk/page.aspx?o=CG038quickrefguide. Accessed May 15, 2007. 24. Gorobets LN, Bulanov VS, Litvinov AV. Chastota vstrechaemosti nejroehndokrinnyh disfunkcij u bol'nyh s paranoidnoj shizofreniej v usloviyah ambulatornoj praktiki. Psihiatriya i psihofarmakoterapiya. Zhurnal im PB Gannushkina. 2016;10(3):27–30. Russian. 25. Gorobets LN, Mazo GE. Giperprolaktinemiya pri ispol'zovanii antipsihotikov vtorogo pokoleniya: principy profilaktiki, diagnostiki i korrekcii. Obozrenie psihiatrii i medicinskoj psihologii im VM Bekhtereva. 2017;1:63–9. Russian. 26. Melmed Sh, Casanueva FF, Hoffmann AR, et al. Diagnostic and treatment of hyperprolactinemia: an Endocrine society clinical practical guideline. J Clin Endocr Metab. Feb. 2011;96(2):273–88. 27. Mel'nichenko GA, Rozhinskaya LYа, Dzeranova LK i dr. Giperprolaktinemiya: klinika, diagnostika, differencial'naya diagnostika, metody lecheniya. Moscow; 2013. 19 p. Russian.
DOI: http://dx.doi.org/10.24411/1560-957X-2018-1%25x
Метрики статей
Metrics powered by PLOS ALM